NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis $4.21 +0.05 (+1.20%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$4.22 +0.00 (+0.12%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Relmada Therapeutics Stock (NASDAQ:RLMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Relmada Therapeutics alerts:Sign Up Key Stats Today's Range$3.82▼$4.7150-Day Range$3.10▼$4.5252-Week Range$3.07▼$8.00Volume1.74 million shsAverage Volume1.68 million shsMarket Capitalization$449.08 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing investigational treatments for central nervous system disorders, with a focus on depression. The company’s work centers on advancing drug candidates through clinical research; it does not have an approved commercial product. Its best-known candidate, REL-1017 (esmethadone), is an oral compound that acts on NMDA receptors. Relmada has studied it as an add-on treatment for adults with major depressive disorder who have not responded adequately to existing antidepressants. Relmada’s development efforts have included clinical trials in the United States. Its pipeline and programs may change as research progresses, and its investigational treatments have not been established as safe or effective for any use by regulatory authorities.AI Generated. May Contain Errors. Read More Relmada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreRLMD MarketRank™: 3.109652002625 of 5 starsRelmada Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 331st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingRelmada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRelmada Therapeutics has a consensus price target of $12.00, representing about 185.0% upside from its current price of $4.21.Amount of Analyst CoverageRelmada Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Relmada Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Relmada Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.88% of the float of Relmada Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 6.36.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 11.01%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.46 News SentimentRelmada Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Relmada Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for RLMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $843,990.00 in company stock, which represents 0.1879% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $843,990.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders14.50% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relmada Therapeutics' insider trading history. Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RLMD Stock News HeadlinesRelmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13 at 9:51 AM | marketscreener.comMRelmada (RLMD) Q3 2026 Earnings Call TranscriptNovember 13 at 9:51 AM | finance.yahoo.comThis is likely to EXPLODEDr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.November 14 at 1:00 AM | Weiss Ratings (Ad)Relmada Therapeutics, Inc. (RLMD) Q3 2026 Earnings Call TranscriptNovember 12 at 11:00 PM | seekingalpha.comRelmada Therapeutics Q3 Loss NarrowsNovember 12 at 6:35 PM | marketscreener.comMRelmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12 at 4:05 PM | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Average Price Target of $12.00 According to AnalystsNovember 5, 2026 | americanbankingnews.comRelmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in LondonNovember 4, 2026 | globenewswire.comSee More Headlines RLMD Stock Analysis - Frequently Asked Questions How have RLMD shares performed this year? Relmada Therapeutics' stock was trading at $4.83 at the start of the year. Since then, RLMD shares have decreased by 12.8% and is now trading at $4.21. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted its quarterly earnings data on Thursday, November, 12th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03. Read the conference call transcript. When did Relmada Therapeutics IPO? Relmada Therapeutics (RLMD) raised $0 in an initial public offering on Thursday, October 10th 2019. The company issued 5,000,000 shares at a price of $0.00 per share. Who are Relmada Therapeutics' major shareholders? Top institutional shareholders of Relmada Therapeutics include State Street Corp (3.10%), Marshall Wace LLP (0.57%), HighVista Strategies LLC (0.39%) and Profund Advisors LLC (0.18%). Insiders that own company stock include Maged Shenouda, Paul Edward Kelly, Chuck Ence, Sergio Traversa and Charles J Casamento. View institutional ownership trends. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Relmada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relmada Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), PayPal (PYPL), Tesla (TSLA), Johnson & Johnson (JNJ), Micron Technology (MU) and Visa (V). Company Calendar Last Earnings11/12/2026Today11/14/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RLMD's financial health is in the Yellow zone, according to TradeSmith. RLMD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RLMD CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees17Year Founded2004Price Target and Rating Average Price Target for Relmada Therapeutics$12.00 High Price Target$19.00 Low Price Target$8.00 Potential Upside/Downside+185.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.51% Return on Assets-35.94% Debt Debt-to-Equity RatioN/A Current Ratio29.52 Quick Ratio29.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book3.57Miscellaneous Outstanding Shares106,670,000Free Float91,203,000Market Cap$449.08 million OptionableOptionable Beta0.62 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:RLMD) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
